Raffa Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21 Hold
1
– – ﹤0.01% 1592
2026
Q2
$26 Hold
1
– – ﹤0.01% 1562
2026
Q1
$19 Buy
+1
New +$20 ﹤0.01% 1483
2021
Q2
– Sell
-1
Closed -$57 – 1101
2021
Q1
$57 Hold
1
– – ﹤0.01% 1098
2020
Q4
$84 Buy
+1
New +$60 ﹤0.01% 909

Other funds holding DNLI

Raffa Wealth Management's DNLI Position: Q3 2026 in Review

Raffa Wealth Management held its Denali Therapeutics (DNLI) position steady in Q3 2026 at 1 share worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

Raffa Wealth Management first reported a position in DNLI in Q4 2020 and has held it in 5 quarters since. The position peaked at $84 in Q4 2020. 287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Raffa Wealth Management held 1 share of Denali Therapeutics worth $21 as of Q3 2026.
  • Raffa Wealth Management left its Denali Therapeutics share count unchanged in Q3 2026.
  • Denali Therapeutics made up ﹤0.01% of Raffa Wealth Management's portfolio in Q3 2026, its #1592 holding.
  • Raffa Wealth Management first reported a position in Denali Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Raffa Wealth Management's Denali Therapeutics position peaked at $84 in Q4 2020.
  • 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Raffa Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.